Navigating complexity: The Supera’s triumph in femoropopliteal lesions
Vascular · 2025
DOI: 10.1177/17085381241246321 ↗Kurz gefasst
Fachartikel in der Zeitschrift Vascular, 2025. Verfasst von Luis Loureiro und 5 weiteren Autor:innen. Beteiligte Einrichtung: Angiology and Vascular Surgery Department, Centro Hospitalar Universitário de Santo António, Porto, Portugal. Hauptthemen laut MEDLINE: Popliteal Artery, Femoral Artery, Peripheral Arterial Disease, Stents. Die Arbeit nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Introduction
The femoropopliteal sector endovascular treatment is particularly challenging due to its high tortuosity and torsional forces. Better results are still needed to ensure the long-term patency of stenting in this area. The Supera stent appears to change this paradigm.
Methods
This single-center retrospective cohort study aims to evaluate the efficacy and safety of femoropopliteal stenting with Supera in a real-world population. Seventy-nine patients were treated between January 2015 and December 2020, and the results are reported with a median follow-up of 28 months.
Results
Indications for revascularization were chronic limb-threatening ischemia with tissue loss (73.6%) or ischemic rest pain (17.7%) and claudication (7.6%). Thirty-six patients (45.6%) were classified as GLASS stage III according to the Global Limb Anatomic Staging System, with 65.8% and 30.4% in grades 3 and 4 of femoropopliteal and infrapopliteal sectors, respectively. The 36-month primary, primary-assisted, and secondary patency rates were 68.6%, 72.0%, and 79.0%, respectively, with an amputation-free survival rate of 86.6%. There was no significant difference between primary patency rates in GLASS stages I–II compared with GLASS stage III (36-month primary patency rates of 72% vs 63% respectively, p = 0.342) nor in amputation-free survival (88% vs 84%, p = 0.877). After adjusting for potential confounders, only the stent conformation significantly affected the primary patency rates, with a higher hazard of reintervention for the elongated (HR = 3.179; p = 0.36; CI 1.081–9.347) and the compressed (HR = 3.014; p = 0.42; CI 1.039–8.746) forms.
Conclusions
The 36-month patency of the Supera stents in our real-world cohort was similar to other reported series. The GLASS stage did not interfere with the stent patency, proving it is a good choice even in the most adverse anatomy patients. Only the non-nominal stent conformation affected the primary patency rates in our patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Angiology and Vascular Surgery Department, Centro Hospitalar Universitário de Santo António, Porto, Portugal.
ORCID-Profile: Luis Loureiro, Carlos Veterano
Zitieren
APA
Loureiro, L., Pinelo, A., Veterano, C., Rocha, H., Castro, J., & Machado, R. (2025). Navigating complexity: The Supera’s triumph in femoropopliteal lesions. Vascular. https://doi.org/10.1177/17085381241246321
Vancouver
Loureiro L, Pinelo A, Veterano C, Rocha H, Castro J, Machado R. Navigating complexity: The Supera’s triumph in femoropopliteal lesions. Vascular. 2025. doi:10.1177/17085381241246321
BibTeX
@article{Loureiro2025,
author = {Loureiro, Luis and Pinelo, Andreia and Veterano, Carlos and Rocha, Henrique and Castro, João and Machado, Rui},
title = {Navigating complexity: The Supera’s triumph in femoropopliteal lesions},
journal = {Vascular},
year = {2025},
doi = {10.1177/17085381241246321}
}
EUVIMED